ArticleAmerican journal of cancer research2025
Development of a prognostic model for cervical cancer based on inflammation-related gene signatures and immune microenvironment regulation.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the molecular basis ofBioinformatics advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo develop a prognostic model for cervical cancer by integrating inflammation-related gene signatures and clinical factors, aimed at improving patient outcome prediction and exploring the role of immune microenvironment regulation in tumor progression.
methodsThis retrospective study analyzed 150 cervical cancer patients from Taiyuan Maternal and Child Health Hospital, diagnosed between January 2019 and January 2022. Patients were categorized into a poor prognosis (n=60) and a good prognosis group (n=90) based on prognosis. The study evaluated the prognostic value of inflammation-related gene expression on overall survival (OS) and progression-free survival (PFS). MMP-9, IL-6, and COX-2 expression levels were stratified as high or low based on median values.
resultsPro-inflammatory genes (TNF-alpha, IL-6, MMP-9, and COX-2) were significantly higher in the poor prognosis group, while IL-10 levels were lower (all P<0.001). Multivariate analysis identified independent risk factors for poor prognosis, including HPV infection status, MMP-9, IL-6, TNF-alpha, and lymph node involvement. A nomogram incorporating these factors demonstrated strong discrimination (AUC 0.83) and effective poor outcome prediction. Elevated levels of MMP-9, IL-6, and COX-2 correlated with poor OS and PFS, highlighting their potential as prognostic markers and therapeutic targets. These gene expression alterations were also associated with immune microenvironment dysregulation, suggesting their role in immune evasion and chronic inflammation in tumors.
conclusionA prognostic model for cervical cancer was developed integrating inflammation-related gene signatures and clinical factors. Elevated MMP-9, IL-6, and COX-2 expression are linked to poor prognosis and immune microenvironment disruption, offering a promising approach for personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.